Nonprostate Cancer Deaths Best Predict Long-Term Survival in Men Aged ≤59 Years Treated With Low Dose Rate Brachytherapy With or Without Supplemental Therapies: A Mandate for Health Enhancement
{{output}}
Purpose: Despite favorable biochemical and functional outcomes in younger patients treated with prostate brachytherapy, overall survival remains compromised by a plethora of nonprostate cancer deaths, especially those attributabl... ...
